Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2025
Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Sep 27, 2023
Emerging Company Profile
Biotheus: fully-integrated mAb platform for optimized fast-follower products
China-based Biotheus goes from discovery to IND submission in about two years
BioCentury | Jun 30, 2023
Emerging Company Profile
Ratio: tuning the pharmacokinetics of radiotherapies
The company’s Trillium platform combines the tumor penetration of small molecules with the staying power of mAbs for its actinium-225 therapies
BioCentury | Mar 6, 2023
Finance
As clinical evidence mounts for bispecific, VCs back Bicara with $108M series B
Red Tree branches beyond West Coast sweet spot to co-lead with RA Capital in backing Biocon spinout
BioCentury | Nov 12, 2022
Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
Items per page:
1 - 10 of 58